

BA/BE

Large Molecules

IVRT/IVPT

BA/BE

| Analyte | Matrix | Sensitivity | Method | Status |
|---|--------------|-----------------|----------|----------------------|
| 15 Hydroxy Lubiprostone | Human Plasma | 1.0 pg/mL | LC/MS/MS | Validated |
| 17-Desacetyl Norgestimate (Norelgestromin) | Human Plasma | 0.02 ng/mL | LC/MS/MS | Validated |
| 2-pyridyl acetic acid (metabolite of Betahistine) | Human Plasma | 5.0 ng/mL | LC/MS/MS | Revalidation Pending |
| 3-Keto Desogestrel | Human Plasma | 50.0 pg/mL | LC/MS/MS | Validated |
| 6-MNA | Human Plasma | 0.2 µg/mL | LC/MS/MS | Validated |
| Abacavir and Lamivudine | Human Plasma | 0.1/0.05 µg/mL | LC/MS/MS | Validated |
| Abiraterone | Human Plasma | 0.2 ng/mL | LC/MS/MS | Validated |
| Abiraterone | Human Plasma | 1.0 ng/mL | LC/MS/MS | Validated |
| Abiraterone | Human Plasma | 5.0 ng/mL | LC/MS/MS | Validated |
| Acalabrutinib & Acalabrutinib Metabolite 27 | Human Plasma | 3.0/3.0 ng/mL | LC/MS/MS | Validated |
| Acalabrutinib and Acalabrutinib Metabolite 27 | Human Plasma | 3.0/3.0 ng/mL | LC/MS/MS | Validated |
| Acamprosate | Human Plasma | 1.0 ng/mL | LC/MS/MS | Revalidation Pending |
| Acepromazine (partial) | Dog Plasma | 1 ng/mL | LC/MS/MS | Validated |
| Acetaminophen | Human Plasma | 0.1 µg/mL | LC/MS/MS | Validated |
| Acetazolamide | Human Plasma | 0.03 µg/mL | LC/MS/MS | Validated |
| Acetazolamide | Human Plasma | 0.3 µg/mL | LC/MS/MS | Validated |
| Acyclovir | Human Plasma | 5.0 ng/mL | LC/MS/MS | Validated |
| Agomelatine | Human Plasma | 0.05 ng/mL | LC/MS/MS | Validated |
| Albendazole and Albendazole Sulfoxide | Human Plasma | 0.25/2.5 ng/mL | LC/MS/MS | Validated |
| Albuterol | Human Plasma | 10.0 pg/mL | LC/MS/MS | Validated |
| Albuterol | Human Plasma | 0.2 ng/mL | LC/MS/MS | Validated |
| Alectinib | Human Plasma | 2.0 ng/mL | LC/MS/MS | Validated |
| Alendronate | Human Plasma | 0.5000 ng/mL | LC/MS/MS | Validated |
| Alfuzosin | Human Plasma | 0.1 ng/mL | LC/MS/MS | Validated |
| Allopurinol | Human Plasma | 0.02 µg/mL | LC/MS/MS | Validated |
| Allopurinol and Oxypurinol | Human Plasma | 0.02/0.04 µg/mL | LC/MS/MS | Validated |
| Almotriptan | Human Plasma | 0.5 ng/mL | LC/MS/MS | Validated |
| Alosetron | Human Plasma | 0.05 ng/mL | LC/MS/MS | Validated |
| Alprazolam | Human Plasma | 1.0 ng/mL | LC/MS/MS | Revalidation Pending |
| Alvimopan and Metabolite ADL-08-0011 | Human Plasma | 0.05/0.01 ng/mL | LC/MS/MS | Validated |
| Amantadine | Human Plasma | 2.0 ng/mL | LC/MS/MS | Validated |
| Ambrisentan | Human Plasma | 10.0 ng/mL | LC/MS/MS | Validated |
| Amiloride | Human Plasma | 0.1 ng/mL | LC/MS/MS | Validated |
| Amiodarone | Human Plasma | 3.0 ng/mL | LC/MS/MS | Validated |
| Amiodarone & N-Desethylamiodarone | Human Plasma | 4.0/2.0 ng/mL | LC/MS/MS | Revalidation Pending |
| Amitriptyline and Nortriptyline | Human Plasma | 0.12/0.04 ng/mL | LC/MS/MS | Validated |
| Amitriptyline and Nortriptyline | Human Plasma | 0.02/0.01 ng/mL | LC/MS/MS | Validated |
| Amlodipine | Human Plasma | 0.1000 ng/mL | LC/MS/MS | Validated |
| Amlodipine | Human Plasma | 0.05 ng/mL | LC/MS/MS | Validated |
| Amoxicillin and Clavulanic Acid | Human Plasma | 0.05/0.01 µg/mL | LC/MS/MS | Validated |
| Amoxicillin/Clavulanate Acid | Cat Plasma | 50/10 ng/mL | LC/MS/MS | Validated |
| Amoxicillin/Clavulanate Acid | Dog Plasma | 50/10 ng/mL | LC/MS/MS | Validated |
| Amphetamine (mix) | Human Plasma | 0.4 ng/mL | LC/MS/MS | Validated |
| Anastrozole | Human Plasma | 0.2 ng/mL | LC/MS/MS | Validated |
| Apalutamide | Human Plasma | 10.0 ng/mL | LC/MS/MS | Validated |

| | | | | |
|---|--------------|-------------------------|----------|----------------------|
| Apixaban | Human Plasma | 1.0 ng/mL | LC/MS/MS | Validated |
| Apremilast | Human Plasma | 2.0 ng/mL | LC/MS/MS | Validated |
| Aripiprazole | Human Plasma | 2.0 ng/mL | LC/MS/MS | Validated |
| Aripiprazole and Dehydro Aripiprazole | Human Plasma | 2.0/0.5 ng/mL | LC/MS/MS | Validated |
| Armodafinil | Human Plasma | - | LC/MS/MS | Under Development |
| Asenapine | Human Plasma | 0.05 ng/mL | LC/MS/MS | Validated |
| Asenapine and N-Desmethyl Asenapine | Human Plasma | 0.05/0.04 ng/mL | LC/MS/MS | Validated |
| Atazanavir | Human Plasma | 20.0 ng/mL | LC/MS/MS | Validated |
| Atenolol | Human Plasma | 5.0 ng/mL | LC/MS/MS | Validated |
| Atomoxetine | Human Plasma | - | LC/MS/MS | Under Consideration |
| Atorvastatin | Human Plasma | 0.25 ng/mL | LC/MS/MS | Validated |
| Atorvastatin, 2-Hydroxy Atorvastatin and 4-Hydroxy Atorvastatin | Human Plasma | 0.25/0.25/0.05 ng/mL | LC/MS/MS | Validated |
| Atovaquone | Human Plasma | 25 ng/mL | LC/MS/MS | Validated |
| Atovaquone | Human Plasma | 0.1 µg/mL | LC/MS/MS | Validated |
| Avanafil | Human Plasma | 0.01 µg/mL | LC/MS/MS | Validated |
| Azilsartan | Human Plasma | 0.04 µg/mL | LC/MS/MS | Validated |
| Azithromycin | Human Plasma | 5.0 ng/mL | LC/MS/MS | Validated |
| Azithromycin | Human Plasma | 2.0 ng/mL | LC/MS/MS | Validated |
| Baclofen | Human Plasma | 3.0 ng/mL | LC/MS/MS | Validated |
| Balsalazide | Human Plasma | 1.0 ng/mL | LC/MS/MS | Validated |
| Beclomethasone dipropionate and 17-BMP | Human Plasma | 10 & 20 pg/mL | LC/MS/MS | Ready for Validation |
| Benazepril & Benazeprilat | Human Plasma | 1.0/1.0 ng/mL | LC/MS/MS | Revalidation Pending |
| Biperiden | Human Plasma | - | LC/MS/MS | Under Consideration |
| Bisoprolol | Human Plasma | 0.5 ng/mL | LC/MS/MS | Validated |
| Bosentan | Human Plasma | 10.0 ng/mL | LC/MS/MS | Validated |
| Bosutinib | Human Plasma | - | LC/MS/MS | Under Development |
| Brexiprazole | Human Plasma | 0.3 ng/mL | LC/MS/MS | Validated |
| BrexPiprazole & DM-3411 | Human Plasma | 0.3/0.3 ng/mL | LC/MS/MS | Validated |
| Bromocriptine | Human Plasma | 20.0 pg/mL | LC/MS/MS | Revalidation Pending |
| Budesonide | Human Plasma | 10.0 pg/mL | LC/MS/MS | Validated |
| Budesonide | Human Plasma | 25.0 pg/mL | LC/MS/MS | Validated |
| Budesonide | Human Plasma | 50.0 pg/mL | LC/MS/MS | Validated |
| Bumetanide | Human Plasma | 0.3 ng/mL | LC/MS/MS | Validated |
| Buprenorphine | Human Plasma | 0.02 ng/mL | LC/MS/MS | Validated |
| Buprenorphine and Norbuprenorphine | Human Plasma | 0.02 ng/mL/0.02 ng/mL | LC/MS/MS | Validated |
| Bupropion, Hydroxy bupropion, Threo dihydrobupropion and Erythro dihydrobupropion | Human Plasma | 0.5/1.5/0.5/0.625 ng/mL | LC/MS/MS | Validated |
| Bupropion, Hydroxybupropion, Erythro-Dihydrobupropion, Threo-Dihydrobupropion | Human Plasma | 2.0/10.0/2.0/10.0 ng/mL | LC/MS/MS | Validated |
| Cabozantinib | Human Plasma | 5.0 ng/mL | LC/MS/MS | Validated |
| Caffeine and Paraxenthine | Human Plasma | - | LC/MS/MS | Under Development |
| Calcitriol | Human Plasma | 10 pg/mL | LC/MS/MS | Validated |
| Calcitriol (Higher Range) | Human Plasma | 10 pg/mL | LC/MS/MS | Validated |
| Canagliflozin | Human Plasma | 7.5 ng/mL | LC/MS/MS | Validated |
| Candesartan | Human Plasma | 1.0 ng/mL | LC/MS/MS | Validated |
| Candesartan | Human plasma | 0.2 ng/mL | LC/MS/MS | Validated |
| Cannabidiol | Human Plasma | 0.1 ng/mL | LC/MS/MS | Validated |
| Capecitabine | Human Plasma | 10.0 ng/mL | LC/MS/MS | Validated |
| Carbamazepine | Human Plasma | 0.1 µg/mL | LC/MS/MS | Validated |
| Carbamazepine | Human Plasma | 25.0 ng/mL | LC/MS/MS | Validated |
| Carbamazepine and Carbamazepine 10, 11 epoxide | Human Plasma | 25.0/2.5 ng/mL | LC/MS/MS | Validated |
| Carbamazepine and Carbamazepine 10, 11 epoxide | Human Plasma | 0.1/0.02 µg/mL | LC/MS/MS | Validated |
| Carbidopa | Human Plasma | 0.5 ng/mL | LC/MS/MS | Validated |
| Cariprazine | Human Plasma | 10.0 pg/mL | LC/MS/MS | Validated |
| Carprofen | Dog Plasma | 0.1 µg/mL | LC/MS/MS | Validated |
| Cefixime | Human Plasma | 50.0 ng/mL | LC/MS/MS | Revalidation Pending |
| Cefpodoxime | Dog Plasma | 0.375 µg/mL | LC/MS/MS | Validated |
| Ceftriaxone | Human Plasma | 3.0 µg/mL | LC/MS/MS | Validated |

| | | | | |
|--|-------------------|---------------------|----------|----------------------|
| Cefuroxime | Human Plasma | 0.20 µg/mL | LC/MS/MS | Revalidation Pending |
| Celecoxib | Human Plasma | 10.0 ng/mL | LC/MS/MS | Validated |
| Cephalexin | Human Plasma | 0.5 µg/mL | LC/MS/MS | Revalidation Pending |
| Cevimeline | Human Plasma | 1.0 ng/mL | LC/MS/MS | Validated |
| Chloral Hydrate | Human Plasma | 0.5 ng/mL | LC/MS/MS | Validated |
| Chlorpromazine and 7-Hydroxy Chlorpromazine | Human Plasma | 0.05/0.025 ng/mL | LC/MS/MS | Validated |
| Chlorpromazine and 7-Hydroxy Chlorpromazine | Human Plasma | 0.5/0.1 ng/mL | LC/MS/MS | Validated |
| Chlorthalidone | Human Whole Blood | 15.0 ng/mL | LC/MS/MS | Validated |
| Chlorthalidone | Human Plasma | 5.0 ng/mL | LC/MS/MS | Revalidation Pending |
| Chlorthalidone | Human Plasma | 2.0 ng/mL | LC/MS/MS | Revalidation Pending |
| Cinacalcet | Human Plasma | 0.25 ng/mL | LC/MS/MS | Validated |
| Ciprofloxacin | Human Plasma | 30.0 ng/mL | LC/MS/MS | Validated |
| Clarithromycin and 14-Hydroxyclarithromycin | Human Plasma | 10.0/5.0 ng/mL | LC/MS/MS | Validated |
| Clevidipine and Clevidipine carboxylic acid (H152/81) | Human Plasma | - | LC/MS/MS | Under Development |
| Clobazam/N-Desmethylclobazam | Human Plasma | 2.5/1.0 ng/mL | LC/MS/MS | Validated |
| Clomipramine | Dog Plasma | 2 ng/mL | LC/MS/MS | Validated |
| Clomipramine and N-Desmethyl Clomipramine | Human Plasma | 1.5/0.3 ng/mL | LC/MS/MS | Validated |
| Clomipramine and N-Desmethyl Clomipramine | Human Plasma | 0.25/0.05 ng/mL | LC/MS/MS | Validated |
| Clonidine | Human Plasma | 40.00 pg/mL | LC/MS/MS | Validated |
| Clonidine | Human Plasma | 0.04 ng/mL | LC/MS/MS | Validated |
| Clonidine | Human Plasma | 5.0 pg/mL | LC/MS/MS | Validated |
| Clopidogrel | Human Plasma | 0.01 ng/mL | LC/MS/MS | Validated |
| Clopidogrel & Clopidogrel Acid | Human Plasma | 0.005/2.5 ng/mL | LC/MS/MS | Revalidation Pending |
| Clopidogrel, 2-Oxo Clopidogrel and Clopidogrel H4 Metabolite | Human Plasma | 0.02/0.02/0.1 ng/mL | LC/MS/MS | Validated |
| Clozapine | Human Plasma | 5.0 ng/mL | LC/MS/MS | Validated |
| Colchicine | Human Plasma | 0.02 ng/mL | LC/MS/MS | Validated |
| Crisaborole | Human Plasma | 0.5 ng/mL | LC/MS/MS | Validated |
| Cyclobenzaprine | Human Plasma | 0.01 ng/mL | LC/MS/MS | Validated |
| Cyclobenzaprine | Human Plasma | 0.2 ng/mL | LC/MS/MS | Validated |
| Cycloserine | Human Plasma | 0.2 µg/mL | LC/MS/MS | Validated |
| Cyclosporine | Dog Blood | 5.0 ng/mL | LC/MS/MS | Validated |
| Cyproheptadine (Liquid-Liquid Method) | Human Plasma | 0.05 ng/mL | LC/MS/MS | Validated |
| Cyproheptadine (Protein Precipitation Method) | Human Plasma | 0.05 ng/mL | LC/MS/MS | Validated |
| Dabigatran (Free & Total) | Human Plasma | 1.0/1.201 ng/mL | LC/MS/MS | Validated |
| Daclatasvir | Human Plasma | 5.0 ng/mL | LC/MS/MS | Validated |
| Dalfampridine | Human Plasma | 0.2 ng/mL | LC/MS/MS | Validated |
| Dapagliflozin | Human Plasma | 1.0 ng/mL | LC/MS/MS | Validated |
| Dapsone | Human Plasma | 0.05 ng/mL | LC/MS/MS | Validated |
| Dapsone low range | Human Plasma | 5.000 pg/mL | LC/MS/MS | Validated |
| Darunavir | Human Plasma | 0.025 µg/mL | LC/MS/MS | Validated |
| Dasatinib | Human Plasma | 1.0 ng/mL | LC/MS/MS | Validated |
| Deferasirox | Human Plasma | 0.1 µg/mL | LC/MS/MS | Validated |
| Deracoxib | Dog Plasma | 5.0 ng/mL | LC/MS/MS | Validated |
| Descarboethoxyloratadine | Human Plasma | 0.05 ng/mL | LC/MS/MS | Revalidation Pending |
| Desloratadine | Human Plasma | 0.04 ng/mL | LC/MS/MS | Validated |
| Desvenlafaxine | Human Plasma | 2.0 ng/mL | LC/MS/MS | Validated |
| Dexamethasone | Human Plasma | 0.5 ng/mL | LC/MS/MS | Validated |
| Dexamphetamine | Human Plasma | 0.5 ng/mL | LC/MS/MS | Validated |
| Dexlansoprazole | Human Plasma | 10.0 ng/mL | LC/MS/MS | Validated |
| Dexmethylphenidate | Human Plasma | 0.1000 ng/mL | LC/MS/MS | Validated |
| Dextromethorphan | Human Plasma | 0.1 ng/mL | LC/MS/MS | Validated |
| Diclofenac | Human Plasma | 5 ng/mL | LC/MS/MS | Validated |
| Diclofenac | Human Plasma | 0.04 ng/mL | LC/MS/MS | Validated |
| Diclofenac | Human Plasma | 10.0 ng/mL | LC/MS/MS | Validated |
| Diclofenac | Human Plasma | 0.025 µg/mL | LC/MS/MS | Validated |
| Diclofenac/Esomeprazole (combined single method) | Human Plasma | 5.0/2.5 ng/mL | LC/MS/MS | Validated |
| Dicyclomine (Dicycloverine) | Human Plasma | 0.3 ng/mL | LC/MS/MS | Validated |

| | | | | |
|--|-------------------|--------------------------|----------|----------------------|
| Dicyclomine (Dicycloverine) | Human Plasma | 1.0 ng/mL | LC/MS/MS | Validated |
| Didanosine | Human Plasma | 10.0 ng/mL | LC/MS/MS | Validated |
| Dienogest | Human Plasma | 0.5 ng/mL | LC/MS/MS | Validated |
| Diflunisal | Human Plasma | 1.0 µg/mL | LC/MS/MS | Validated |
| Digoxin | Human Plasma | 0.025 ng/mL | LC/MS/MS | Validated |
| Diltiazem | Human Plasma | 0.6 ng/mL | LC/MS/MS | Validated |
| Diltiazem, Desacetyl Diltiazem & N-Desmethyl Diltiazem | Human Plasma | 0.6/0.12/0.21 ng/mL | LC/MS/MS | Validated |
| Dipyridamole | Human Plasma | 5.0 ng/mL | LC/MS/MS | Validated |
| Dolutegravir | Human Plasma | 20.0 ng/mL | LC/MS/MS | Validated |
| Donepezil | Human Plasma | 0.1 ng/mL | LC/MS/MS | Validated |
| Donepezil and 6-O-Desmethyl Donepezil | Human Plasma | 0.1/0.02 ng/mL | LC/MS/MS | Validated |
| Doxazosin | Human Plasma | 0.1 ng/mL | LC/MS/MS | Validated |
| Doxepin and Nordoxepin | Human Plasma | 20.0/2.0 pg/mL | LC/MS/MS | Validated |
| Doxepin and Nordoxepin | Human Plasma | 20.0/10.0 pg/mL | LC/MS/MS | Validated |
| Doxepin and Nordoxepin | Human Plasma | 0.2/0.05 ng/mL | LC/MS/MS | Validated |
| Doxycycline | Human Plasma | 20.0 ng/mL | LC/MS/MS | Validated |
| Dronedarone and Desbutyl Dronedarone | Human Plasma | 0.5/0.5 ng/mL | LC/MS/MS | Validated |
| Drospirenone | Human Plasma | 0.5 ng/mL | LC/MS/MS | Validated |
| Drotaverine | Human Plasma | 2.0 ng/mL | LC/MS/MS | Validated |
| Droxidopa | Human Plasma | 5.5 ng/mL | LC/MS/MS | Validated |
| Duloxetine | Human Plasma | 1.0 ng/mL | LC/MS/MS | Validated |
| Dutasteride | Human Plasma | 0.05 ng/mL | LC/MS/MS | Validated |
| Dydrogesterone | Human Plasma | 50.0 pg/mL | LC/MS/MS | Validated |
| Edoxaban | Human Plasma | 5.0 ng/mL | LC/MS/MS | Validated |
| E-Doxepin and Z-Doxepin | Human Plasma | 0.2565 and 0.04470 ng/mL | LC/MS/MS | Validated |
| Efavirenz | Human Plasma | 10.0 ng/mL | LC/MS/MS | Validated |
| Elagolix | Human Plasma | 5.0 ng/mL | LC/MS/MS | Validated |
| Eletriptan | Human Plasma | 0.5 ng/mL | LC/MS/MS | Validated |
| Eltrombopag | Human Plasma | 0.05 µg/mL | LC/MS/MS | Validated |
| Eltrombopag | Human Plasma | 0.01 µg/mL | LC/MS/MS | Validated |
| Eluxadoline | Human Plasma | 0.1 ng/mL | LC/MS/MS | Validated |
| Eluxadoline | Human Plasma | 0.01 ng/mL | LC/MS/MS | Validated |
| Empagliflozin | Human Plasma | 1.0 ng/mL | LC/MS/MS | Validated |
| Emtricitabine | Human Plasma | 5.0 ng/mL | LC/MS/MS | Validated |
| Enalapril and Enalaprilat | Human Plasma | 0.5/0.5 ng/mL | LC/MS/MS | Validated |
| Enrofloxacin | Dog Plasma | 10.0 ng/mL | LC/MS/MS | Validated |
| Enrofloxacin | Cat Plasma | 10.0 ng/mL | LC/MS/MS | Validated |
| Entacapone | Human Plasma | 20.0 ng/mL | LC/MS/MS | Validated |
| Entecavir | Human Plasma | 0.04 ng/mL | LC/MS/MS | Validated |
| Enzalutamide | Human Plasma | 0.10 µg/mL | LC/MS/MS | Validated |
| Enzalutamide | Human Plasma | 0.05 µg/mL | LC/MS/MS | Validated |
| Eplerenone | Human Plasma | 0.010 µg/mL | LC/MS/MS | Validated |
| Erlotinib | Human Plasma | 5.0 ng/mL | LC/MS/MS | Validated |
| Erythromycin | Human Plasma | 10.0 ng/mL | LC/MS/MS | Validated |
| Escitalopram | Human Plasma | 0.2 ng/mL | LC/MS/MS | Validated |
| Esomeprazole | Human Plasma | 4.0 ng/mL | LC/MS/MS | Validated |
| Estradiol and Estrone | Human Plasma | 1.000/5.000 pg/mL | LC/MS/MS | Validated |
| Estradiol and Estrone | Human Plasma | 10.0/10.0 pg/mL | LC/MS/MS | Revalidation Pending |
| Ethacrynic acid | Human Plasma | 2.0 ng/mL | LC/MS/MS | Validated |
| Ethinyl Estradiol | Human Plasma | 1 pg/mL | LC/MS/MS | Ready for Validation |
| Ethinyl Estradiol | Human Plasma | 1.0 pg/mL | LC/MS/MS | Validated |
| Etodolac | Human Plasma | 0.1 µg/mL | LC/MS/MS | Validated |
| Everolimus | Human Plasma | - | LC/MS/MS | Under Consideration |
| Everolimus | Human Whole Blood | 0.3 ng/mL | LC/MS/MS | Validated |
| Exemestane | Human Plasma | 0.1 ng/mL | LC/MS/MS | Validated |
| Exemestane | Human Plasma | 0.2 ng/mL | LC/MS/MS | Validated |
| Ezetimibe and Ezetimibe Glucuronide | Human Plasma | 0.025/0.25 ng/mL | LC/MS/MS | Validated |
| Ezetimibe and Ezetimibe Glucuronide | Human Plasma | 0.05/0.9 ng/mL | LC/MS/MS | Validated |
| Famotidine | Human Plasma | 1.0 ng/mL | LC/MS/MS | Validated |
| Febuxostat | Human Plasma | 0.02 µg/mL | LC/MS/MS | Validated |
| Felbamate | Human Plasma | 0.4 µg/mL | LC/MS/MS | Validated |
| Felodipine | Human Plasma | 0.05 ng/mL | LC/MS/MS | Revalidation Pending |
| Fenofibric Acid | Human Plasma | 0.05 µg/mL | LC/MS/MS | Validated |

| | | | | |
|--|-------------------|-------------------|----------|----------------------|
| fenoprofen | Human Plasma | 0.2 ng/mL | LC/MS/MS | Revalidation Pending |
| Fentanyl | Human Plasma | 2.000 pg/mL | LC/MS/MS | Validated |
| Fesoterodine and 5-Hydroxymethyl Tolterodine | Human Plasma | 0.05/0.05 ng/mL | LC/MS/MS | Revalidation Pending |
| Finasteride | Human Plasma | 0.1 ng/mL | LC/MS/MS | Validated |
| Firocoxib | Dog Plasma | 1.0 ng/mL | LC/MS/MS | Validated |
| Flecainide | Human Plasma | 1.0 ng/mL | LC/MS/MS | Validated |
| Fluconazole | Human Plasma | 0.1 µg/mL | LC/MS/MS | Validated |
| Fluconazole | Human Plasma | 0.025 µg/mL | LC/MS/MS | Validated |
| Flucytosine | Human Plasma | 0.05 µg/mL | LC/MS/MS | Validated |
| Flunarizine | Human Plasma | 0.2 ng/mL | LC/MS/MS | Validated |
| Fluoxetine | Human Plasma | 0.2 ng/mL | LC/MS/MS | Validated |
| Fluoxetine and Norfluoxetine | Human Plasma | 0.5/0.5 ng/mL | LC/MS/MS | Validated |
| Fluphenazine | Human Plasma | 15.0 pg/mL | LC/MS/MS | Validated |
| Flupirtine and Acetylated Flupirtine | Human Plasma | 8.0/2.0 ng/mL | LC/MS/MS | Validated |
| Fluvastatin | Human Plasma | 1.0 ng/mL | LC/MS/MS | Revalidation Pending |
| Fluvastatin | Human Plasma | 0.05/0.05 ng/mL | LC/MS/MS | Revalidation Pending |
| Fluvoxamine | Human Plasma | 0.5 ng/mL | LC/MS/MS | Validated |
| Fosfomycin | Human Plasma | 0.5 µg/mL | LC/MS/MS | Ready for Validation |
| Fosinoprilat | Human Plasma | 5.0 ng/mL | LC/MS/MS | Validated |
| Furosemide | Dog Plasma | 5.00 ng/mL | LC/MS/MS | Validated |
| Furosemide | Cat Plasma | 5.00 ng/mL | LC/MS/MS | Validated |
| Furosemide | Human Plasma | 20.0 ng/mL | LC/MS/MS | Validated |
| Gabapentin | Human Plasma | 0.3 µg/mL | LC/MS/MS | Validated |
| Gabapentin | Human Plasma | 20.0 ng/mL | LC/MS/MS | Validated |
| Gemfibrozil | Human Plasma | 0.1 µg/mL | LC/MS/MS | Revalidation Pending |
| Gestodene | Human Plasma | 0.05 ng/mL | LC/MS/MS | Validated |
| Gliclazide | Human Plasma | 0.01 µg/mL | LC/MS/MS | Validated |
| Glipizide | Human Plasma | 5.0 ng/mL | LC/MS/MS | Validated |
| Glyburide | Human Plasma | 1.0 ng/mL | LC/MS/MS | Validated |
| Glycopyrronium | Human Plasma | 2.0 pg/mL | LC/MS/MS | Revalidation Pending |
| Granisetron | Human Plasma | 0.02 ng/mL | LC/MS/MS | Validated |
| Grapiprant | Dog Serum | 5 ng/mL | LC/MS/MS | Validated |
| Guaifenesin | Human Plasma | 20.0 ng/mL | LC/MS/MS | Validated |
| Guanfacine | Human Plasma | 0.05 ng/mL | LC/MS/MS | Validated |
| Haloperidol | Human Plasma | 0.3000 ng/mL | LC/MS/MS | Validated |
| Haloperidol | Human Plasma | 0.01 ng/mL | LC/MS/MS | Validated |
| Haloperidol (Low range) | Human Plasma | 0.02000 ng/mL | LC/MS/MS | Validated |
| Hydralazine | Human Plasma | 0.5000 ng/mL | LC/MS/MS | Validated |
| Hydrochlorothiazide | Human Plasma | 0.5 ng/mL | LC/MS/MS | Validated |
| Hydrochlorothiazide and Olmesartan | Human Plasma | 2.8/24.0 ng/mL | LC/MS/MS | Validated |
| Hydrocortisone | Human Plasma | 4.0 ng /mL | LC/MS/MS | Validated |
| Hydromorphone | Human Plasma | 0.05000 ng/mL | LC/MS/MS | Validated |
| Hydroxychloroquine | Human Whole Blood | 2.0 ng/mL | LC/MS/MS | Validated |
| Hydroxyzine and Cetirizine | Human Plasma | 0.4/1.4 ng/mL | LC/MS/MS | Validated |
| Hyoscine | Human Plasma | - | LC/MS/MS | Under Development |
| Ibrutinib | Human Plasma | 10.0 ng/mL | LC/MS/MS | Ready for Validation |
| Ibrutinib | Human Plasma | 0.4 ng/mL | LC/MS/MS | Validated |
| Ibrutinib | Human Plasma | 1.5 ng/mL | LC/MS/MS | Validated |
| Ibuprofen | Human Plasma | 0.05 µg/mL | LC/MS/MS | Validated |
| Ibuprofen | Human Plasma | 0.2 µg/mL | LC/MS/MS | Validated |
| Imatinib | Human Plasma | 0.05 µg/mL | LC/MS/MS | Validated |
| Imatinib | Human Plasma | 10.0 ng/mL | LC/MS/MS | Validated |
| Imipramine and Desipramine | Human Plasma | 0.5/0.25 ng/mL | LC/MS/MS | Validated |
| Indacaterol | Human Serum | 10.0 pg/mL | LC/MS/MS | Revalidation Pending |
| Indapamide | Human Blood | 2.000 ng/mL | LC/MS/MS | Validated |
| Indapamide | Human Plasma | 1.0 ng/mL | LC/MS/MS | Revalidation Pending |
| Indomethacin | Human Plasma | 0.02 µg/mL | LC/MS/MS | Validated |
| Ipratropium Br. | Human Plasma | 0.5000 ng/mL | LC/MS/MS | Validated |
| Irbesartan | Human Plasma | 20.0 ng/mL | LC/MS/MS | Validated |
| Isosorbide Dinitrate | Human Plasma | 0.5000 ng/mL | LC/MS/MS | Validated |
| Isosorbide dinitrate, 2 mono and 5 mono ISDN | Human Plasma | 0.5/2.0/1.0 ng/mL | LC/MS/MS | Validated |
| Isosorbide Dinitrate, Isosorbide-2-Mononitrate, Isosorbide-5-Mononitrate | Human Plasma | 1.0/2.0/6.0 ng/mL | LC/MS/MS | Revalidation Pending |
| Isosorbide Mononitrate | Human Plasma | 10.0 ng/mL | LC/MS/MS | Validated |

| | | | | |
|--|--------------|----------------------|----------|----------------------|
| Isotretinoin | Human Plasma | 1.000 ng/mL | LC/MS/MS | Validated |
| Isotretinoin High Range (1.000-1500 ng/mL) | Human Plasma | 1.000 ng/mL | LC/MS/MS | Validated |
| Itraconazole & Hydroxy Itraconazole | Human Plasma | 1.0/2.0 ng/mL | LC/MS/MS | Revalidation Pending |
| Ivabradine and N-Desmethyl Ivabradine | Human Plasma | 1.0/0.1 ng/mL | LC/MS/MS | Validated |
| Ivacaftor | Human Plasma | 2.0 ng/mL | LC/MS/MS | Validated |
| Ivermectin (Ivermectin H2B1a) | Human Plasma | 0.2 ng/mL | LC/MS/MS | Validated |
| Ketorolac | Human Plasma | 10.0 ng/mL | LC/MS/MS | Validated |
| Lacosamide | Human Plasma | 0.01 µg/mL | LC/MS/MS | Validated |
| Lamivudine, Zidovudine and Abacavir | Human Plasma | 20.0/20.0/40.0 ng/mL | LC/MS/MS | Validated |
| Lamotrigine | Human Plasma | 10.0 ng/mL | LC/MS/MS | Validated |
| Lamotrigine | Human Plasma | 0.04 µg/mL | LC/MS/MS | Validated |
| Lansoprazole | Human Plasma | 2.0 ng/mL | LC/MS/MS | Validated |
| Ledipasvir | Human Plasma | 3.0 ng/mL | LC/MS/MS | Validated |
| Lenalidomide | Human Plasma | 2.0 ng/mL | LC/MS/MS | Validated |
| Lenvatinib | Human Plasma | 1.0 ng/mL | LC/MS/MS | Validated |
| Letermovir | Human Plasma | 0.2 µg/mL | LC/MS/MS | Validated |
| Letrozole | Human Plasma | 0.5 ng/mL | LC/MS/MS | Validated |
| Leuprolide | Human Serum | 0.08 ng/mL | LC/MS/MS | Validated |
| Levetiracetam | Human Plasma | 0.3 µg/mL | LC/MS/MS | Validated |
| Levodopa & Carbidopa | Human Plasma | 10.00/2.000 ng/mL | LC/MS/MS | Validated |
| Levodopa and Carbidopa | Human Plasma | 10.0/0.5 ng/mL | LC/MS/MS | Validated |
| Levodopa and Carbidopa | Human Plasma | 10.0/1.0 ng/mL | LC/MS/MS | Validated |
| Levofloxacin | Human Plasma | 0.05 µg/mL | LC/MS/MS | Revalidation Pending |
| Levomefolate | Human Plasma | 3.0 ng/mL | LC/MS/MS | Validated |
| Levomefolate | Human Plasma | 1.5 ng/mL | LC/MS/MS | Validated |
| Levomilnacipran | Human Plasma | 1.0 ng/mL | LC/MS/MS | Validated |
| Levonorgestrel | Human Plasma | 0.1 ng/mL | LC/MS/MS | Validated |
| Levothyroxine | Dog Plasma | 5 ng/mL | LC/MS/MS | Validated |
| Levothyroxine | Human Serum | 35.0 ng/mL | LC/MS/MS | Validated |
| Lidocaine | Human Plasma | 0.2 ng/mL | LC/MS/MS | Validated |
| Linagliptin and Metformin | Human Plasma | 0.05/10.0 ng/mL | LC/MS/MS | Validated |
| Linagliptine | Human Plasma | 0.1 ng/mL | LC/MS/MS | Validated |
| Liothyronine | Human Plasma | 0.5 ng/mL | LC/MS/MS | Validated |
| Lisdexamfetamine & Dexamphetamine | Human Plasma | 0.2ng/mL | LC/MS/MS | Validated |
| Lisinopril | Human Plasma | 1.0 ng/mL | LC/MS/MS | Validated |
| Loperamide | Human Plasma | 10.0 pg/mL | LC/MS/MS | Validated |
| Loratadine & Descarboethoxyloratadine | Human Plasma | 0.020/0.020 ng/mL | LC/MS/MS | Revalidation Pending |
| Lorcaserin | Human Plasma | 0.5 ng/mL | LC/MS/MS | Validated |
| Lornoxicam | Human Plasma | 8.0 ng/mL | LC/MS/MS | Validated |
| Losartan & Losartan Carboxylic Acid | Human Plasma | 5.0/7.0 ng/mL | LC/MS/MS | Validated |
| Lovastatin & Lovastatin acid | Human Plasma | 0.1/0.1 ng/mL | LC/MS/MS | Revalidation Pending |
| Lufenuron | Dog Plasma | 5 ng/mL | LC/MS/MS | Validated |
| Lurasidone | Human Plasma | 0.2 ng/mL | LC/MS/MS | Validated |
| Macitentan | Human Plasma | 1.0 ng/mL | LC/MS/MS | Validated |
| Maraviroc | Human Plasma | 10.0 ng/mL | LC/MS/MS | Validated |
| Marbofloxacin | Dog Plasma | 5 ng/mL | LC/MS/MS | Validated |
| Marbofloxacin | Cat Plasma | 5 ng/mL | LC/MS/MS | Validated |
| Maropitant | Dog Plasma | 1 ng/mL | LC/MS/MS | Validated |
| Mebendazole | Human Plasma | 0.1 ng/mL | LC/MS/MS | Validated |
| Medroxyprogesterone acetate | Human Plasma | 0.025 ng/mL | LC/MS/MS | Validated |
| Melatonin | Human Plasma | 10.0 pg/mL | LC/MS/MS | Validated |
| Meloxicam | Dog Plasma | 5.0 ng/mL | LC/MS/MS | Validated |
| Meloxicam | Human Plasma | 5.0 ng/mL | LC/MS/MS | Validated |
| Meloxicam | Human Plasma | - | LC/MS/MS | Under Development |
| Memantine | Human Plasma | 0.5 ng/mL | LC/MS/MS | Validated |
| Mercaptopurine | Human Plasma | 0.5 ng/mL | LC/MS/MS | Validated |
| Mesalamine | Human Plasma | 4.0 ng/mL | LC/MS/MS | Validated |
| Mesalamine | Human Plasma | 2.0 ng/mL | LC/MS/MS | Validated |
| Mesalamine | Human Plasma | 1.0 ng/mL | LC/MS/MS | Validated |
| Mesalamine | Human Plasma | 5.0 ng/mL | LC/MS/MS | Validated |
| Mesalazine | Human Plasma | - | LC/MS/MS | Under Consideration |
| Metaxalone | Human Plasma | 25.0 ng/mL | LC/MS/MS | Validated |

| | | | | |
|---|-------------------|--------------------------|----------|----------------------|
| Metformin | Human Plasma | 10.0 ng/mL | LC/MS/MS | Validated |
| Methazolamide | Human Plasma | 0.1000 µg/mL | LC/MS/MS | Validated |
| Methazolamide | Human Whole Blood | 0.1000 µg/mL | LC/MS/MS | Validated |
| Methenamine | Human Plasma | 0.25 µg/mL | LC/MS/MS | Validated |
| Methenamine | Human Plasma | 0.075 µg/mL | LC/MS/MS | Validated |
| Methocarbamol | Human Plasma | 0.2 µg/mL | LC/MS/MS | Validated |
| Methotrexate | Human Plasma | 3.0 ng/mL | LC/MS/MS | Validated |
| Methotrexate | Human Plasma | 1.0 ng/mL | LC/MS/MS | Validated |
| Methylergonovine | Human Plasma | 0.5 ng/mL | LC/MS/MS | Validated |
| Methylmalonic acid | Human Serum | 10.0 ng/mL | LC/MS/MS | Validated |
| Methylphenidate | Human Whole Blood | 0.1000 ng/mL | LC/MS/MS | Validated |
| Methylphenidate | Human Plasma | 0.1 ng/mL | LC/MS/MS | Validated |
| Methylprednisolone | Human Plasma | 1.0 ng/mL | LC/MS/MS | Validated |
| Metoclopramide | Human Plasma | 0.25 ng/mL | LC/MS/MS | Validated |
| Metolazone | Human Plasma | 0.25 ng/mL | LC/MS/MS | Validated |
| Metolazone | Human Plasma | 0.5 ng/mL | LC/MS/MS | Validated |
| Metoprolol | Human Plasma | 0.3 ng/mL | LC/MS/MS | Validated |
| Metronidazole | Human Plasma | 2.0 ng/mL | LC/MS/MS | Validated |
| Metronidazole | Human Plasma | 0.2 µg/mL | LC/MS/MS | Validated |
| Mexiletine | Human Plasma | 10.0 ng/mL | LC/MS/MS | Validated |
| Midodrine | Human Plasma | 0.2 ng/mL | LC/MS/MS | Validated |
| Midodrine and Desglymidodrine | Human Plasma | 0.25/0.125 ng/mL | LC/MS/MS | Validated |
| Midostaurin, CGP52421 Epimer 2 and CGP62221 (O-Desmethyl Midostaurin) | Human Plasma | 7.5/2.5/5.0 ng/mL | LC/MS/MS | Validated |
| Milbemycin Oxime | Dog Plasma | 1.0/4.0 ng/mL | LC/MS/MS | Validated |
| Miltefosine | Human Plasma | 50.0 ng/mL | LC/MS/MS | Validated |
| Minocycline | Human Plasma | 20.0 ng/mL | LC/MS/MS | Validated |
| Minoxidil | Human Serum | 0.8 ng/mL | LC/MS/MS | Validated |
| Mirabegron | Human Plasma | 0.2 ng/mL | LC/MS/MS | Validated |
| Mirtazapine | Cat Plasma | 1.000 ng/mL | LC/MS/MS | Validated |
| Mirtazapine | Human Plasma | 0.25 ng/mL | LC/MS/MS | Validated |
| Misoprostol | Human Plasma | 7.5 pg/mL | LC/MS/MS | Validated |
| Misoprostol | Human Plasma | - | LC/MS/MS | Under Consideration |
| Misoprostol Low Range | Human Plasma | 5 pg/mL | LC/MS/MS | Ready for Validation |
| Modafinil | Human Plasma | 0.05 µg/mL | LC/MS/MS | Validated |
| Monomethyl Fumarate | Human Plasma | 0.02 µg/mL | LC/MS/MS | Validated |
| Montelukast | Human Plasma | 2.0 ng/mL | LC/MS/MS | Validated |
| Morphine | Human Plasma | TBD | LC/MS/MS | Under Development |
| Moxifloxacin | Human Plasma | 0.025 µg/mL | LC/MS/MS | Validated |
| Mycophenolic Acid | Human Plasma | 0.1 µg/mL | LC/MS/MS | Validated |
| Nadolol | Human Plasma | 1.0 ng/mL | LC/MS/MS | Validated |
| Naproxen | Human Plasma | 0.2 µg/mL | LC/MS/MS | Validated |
| Nateglinide | Human Plasma | 0.05 µg/mL | LC/MS/MS | Validated |
| NCE-1 | Human Plasma | 0.2 ng/mL | LC/MS/MS | Validated |
| NCE-1 | Human Plasma | 2.5 ng/mL | LC/MS/MS | Validated |
| NCE-1 In Urine | Human Urine | 0.02 ng/mL | LC/MS/MS | Validated |
| NCE-1 Metabolite | Human Plasma | 0.1 ng/mL | LC/MS/MS | Validated |
| NCE-1 Metabolite in Urine | Human Urine | 0.05 ng/mL | LC/MS/MS | Validated |
| NCE-2 | Human Plasma | 0.01 ng/mL | LC/MS/MS | Validated |
| Nebivolol | Human Plasma | 0.04 ng/mL | LC/MS/MS | Validated |
| Nevirapine | Human Plasma | 0.03 µg/mL | LC/MS/MS | Validated |
| Niacin and Nicotinic Acid | Human Plasma | 5.0/2.5 ng/mL | LC/MS/MS | Validated |
| Nicotine & Cotinine | Human Plasma | 0.1 ng/mL and 1.00 ng/mL | LC/MS/MS | Ready for Validation |
| Nifedipine | Human Plasma | 0.5 ng/mL | LC/MS/MS | Validated |
| Nifedipine | Human Plasma | 0.2 ng/mL | LC/MS/MS | Validated |
| Nilotinib | Human Plasma | 5.0 ng/mL | LC/MS/MS | Validated |
| Nintedanib | Human Plasma | 0.3 ng/mL | LC/MS/MS | Validated |
| Nitisinone | Human Plasma | 10 ng/mL | LC/MS/MS | Ready for Validation |
| Nitrofurantoin | Human Plasma | 5.0 ng/mL | LC/MS/MS | Validated |
| Nitrofurantoin | Human Plasma | 1.0 ng/mL | LC/MS/MS | Validated |
| Nitroglycerin | Human Plasma | TBD | LC/MS/MS | Under Consideration |
| Nitroso Bumetanide | Rat Plasma | 25 pg/mL | LC/MS/MS | Validated |
| Norethindrone | Human Plasma | 0.1 ng/mL | LC/MS/MS | Validated |
| Norethindrone | Human Plasma | 0.2 ng/mL | LC/MS/MS | Validated |
| Norethindrone | Human Plasma | 0.05 ng/mL | LC/MS/MS | Validated |

| | | | | |
|---|--------------|----------------------|----------|----------------------|
| Norgestimate | Human Plasma | 20 pg/mL | LC/MS/MS | Ready for Validation |
| Norgestimate & 17-Desacetyl Norgestimate | Human Plasma | 2.0/36.0 pg/mL | LC/MS/MS | Revalidation Pending |
| Nortriptyline and 10-Hydroxy Nortriptyline | Human Plasma | 0.2/0.4 ng/mL | LC/MS/MS | Validated |
| Octreotide | Human Plasma | - | LC/MS/MS | Under Consideration |
| Olanzapine | Human Plasma | 0.1 ng/ml | LC/MS/MS | Revalidation Pending |
| Olaparib | Human Plasma | 0.05 µg/mL | LC/MS/MS | Validated |
| Olmesartan | Human Plasma | 10.0 ng/mL | LC/MS/MS | Validated |
| Olopatadine | Human Plasma | 0.05 ng/mL | LC/MS/MS | Validated |
| Omeprazole | Horse Plasma | 1 ng/mL | LC/MS/MS | Validated |
| Omeprazole | Human Plasma | 2.0 ng/mL | LC/MS/MS | Validated |
| Omeprazole | Human Plasma | 5.0 ng/mL | LC/MS/MS | Validated |
| Oseltamivir and Oseltamivir Carboxylic Acid | Human Plasma | 0.5/5.0 ng/mL | LC/MS/MS | Validated |
| Osimertinib | Human Plasma | 0.5 ng/mL | LC/MS/MS | Validated |
| Ospemifene | Human Serum | 3.0 ng/mL | LC/MS/MS | Validated |
| Oxcarbazepine & 10,11-Dihydro-10-Hydroxy-Carbamazepine | Human Plasma | 0.01/0.05 µg/mL | LC/MS/MS | Validated |
| Oxcarbazepine & 10,11-Dihydro-10-Hydroxy-Carbamazepine | Human Plasma | 0.02/0.08 µg/mL | LC/MS/MS | Validated |
| Oxybutynin and Desethyl oxybutynin | Human Plasma | 0.05/0.2 ng/mL | LC/MS/MS | Validated |
| Oxybutynin and N-Desethyl Oxybutynin | Human Plasma | 0.15/0.3 ng/mL | LC/MS/MS | Validated |
| Oxycodone | Human Plasma | 0.2 ng/mL | LC/MS/MS | Ready for Validation |
| Oxymorphone | Human Plasma | - | LC/MS/MS | Under Consideration |
| Palbociclib | Human Plasma | 0.5 ng/mL | LC/MS/MS | Validated |
| Paliperidone | Human Plasma | 0.2 ng/mL | LC/MS/MS | Validated |
| Pantoprazole | Human Plasma | 10.0 ng/mL | LC/MS/MS | Validated |
| Paroxetine | Human Plasma | 0.2 ng/mL | LC/MS/MS | Validated |
| Pazopanib | Human Plasma | 0.5 µg/mL | LC/MS/MS | Validated |
| Pednisolone | Dog Plasma | 0.2 ng/mL | LC/MS/MS | Validated |
| Perampanel | Human Plasma | 1.0 ng/mL | LC/MS/MS | Validated |
| Perindopril / Perindoprilat | Human Plasma | 0.5/0.2 ng/mL | LC/MS/MS | Validated |
| Perindopril and Perindoprilat | Human Plasma | 0.5/0.2 ng/mL | LC/MS/MS | Revalidation Pending |
| Perphenazine | Human Plasma | 0.015 ng/mL | LC/MS/MS | Validated |
| Phenazopyridine | Human Plasma | 0.2 ng/mL | LC/MS/MS | Validated |
| Phenazopyridine & 2,6 Diamino-5-phenylazo-pyridine-3-ol & acetaminophen | Human urine | 6.0/100.0/60.0 ng/mL | LC/MS/MS | Revalidation Pending |
| Phentermine and Topiramate | Human Plasma | - | LC/MS/MS | Under Consideration |
| Phenylpropanolamine | Dog Plasma | 5 ng/mL | LC/MS/MS | Validated |
| Phenytoin | Human Plasma | 10.0 µg/mL | LC/MS/MS | Validated |
| Pimavanserin | Human Plasma | 0.1 ng/mL | LC/MS/MS | Validated |
| Pimobendan | Dog Plasma | 1.000 ng/mL | LC/MS/MS | Validated |
| Pimobendan | Dog Plasma | 0.500 ng/mL | LC/MS/MS | Validated |
| Pindolol | Human Plasma | 1.0 ng/mL | LC/MS/MS | Validated |
| Pioglitazone, Hydroxy pioglitazone and Keto pioglitazone | Human Plasma | 5.0/2.5/2.5 ng/mL | LC/MS/MS | Validated |
| Pirfenidone | Human Plasma | 0.05 µg/mL | LC/MS/MS | Validated |
| Pitavastatin | Human Plasma | 0.2 ng/mL | LC/MS/MS | Validated |
| Pomalidomide | Human Plasma | 0.2 ng/mL | LC/MS/MS | Validated |
| Posaconazole | Human Plasma | 2.0 ng/mL | LC/MS/MS | Validated |
| Potassium | Human urine | 100.0 µg/mL | ICP-OES | Revalidation Pending |
| Pramipexole | Human Plasma | 10.0 pg/mL | LC/MS/MS | Validated |
| Prasugrel active metabolite (R138727) | Human Plasma | 0.2 ng/mL | LC/MS/MS | Validated |
| Prasugrel inactive metabolite (R95913) | Human Plasma | 0.25 ng/mL | LC/MS/MS | Validated |
| Pravastatin | Human Plasma | 0.4 ng/mL | LC/MS/MS | Revalidation Pending |
| Praziquantel | Dog Plasma | 5 ng/mL | LC/MS/MS | Validated |
| Praziquantel | Cat Plasma | 5 ng/mL | LC/MS/MS | Validated |
| Prazosin | Human Plasma | 0.2 ng/mL | LC/MS/MS | Validated |
| Prazosin | Human Plasma | 0.2 ng/mL | LC/MS/MS | Validated |
| Prednisone and prednisolone | Human Plasma | 0.2/2.0 ng/mL | LC/MS/MS | Validated |
| Pregabalin | Human Plasma | 0.05 µg/mL | LC/MS/MS | Validated |
| Pregabalin | Human Plasma | 0.01 µg/mL | LC/MS/MS | Validated |
| Prochlorperazine | Human Plasma | 5.0 pg/mL | LC/MS/MS | Validated |

| | | | | |
|---|-------------------|------------------------|----------|----------------------|
| Progesterone | Human Plasma | 0.5 ng/mL | LC/MS/MS | Validated |
| Progesterone | Human Plasma | 0.05 ng/mL | LC/MS/MS | Validated |
| Promethazine | Human Plasma | 0.5 ng/mL | LC/MS/MS | Validated |
| Propafenone and 5-Hydroxy Propafenone | Human Plasma | 0.2/0.1 ng/mL | LC/MS/MS | Validated |
| Propranolol and 4-Hydroxy Propranolol | Human Plasma | 1.0/0.2 ng/mL | LC/MS/MS | Validated |
| Pyridostigmine | Human Plasma | 0.75 ng/mL | LC/MS/MS | Validated |
| Quetiapine | Human Plasma | 1.0 ng/mL | LC/MS/MS | Validated |
| Rabeprazole | Human Plasma | 2.0 ng/mL | LC/MS/MS | Validated |
| Raloxifene, Raloxifene 4 glucuronide and Raloxifene 6 glucuronide | Human Plasma | 0.01/4.0/0.8 ng/mL | LC/MS/MS | Revalidation Pending |
| Ramipril and Ramiprilat | Human Plasma | 0.1/0.1 ng/mL | LC/MS/MS | Validated |
| Ranitidine | Human Plasma | 10 ng/mL | LC/MS/MS | Validated |
| Ranolazine | Human Plasma | 5.0 ng/mL | LC/MS/MS | Validated |
| Rapamycin | Dog Whole Blood | 0.5 ng/mL | LC/MS/MS | Validated |
| Rapamycin | Cat Whole Blood | 0.5 ng/mL | LC/MS/MS | Validated |
| Rasagiline | Human Plasma | 0.01 ng/mL | LC/MS/MS | Validated |
| Remdesivir & GS-441524 | Human Plasma | 20.0/1.0 ng/mL | LC/MS/MS | Validated |
| Repaglinide | Human Plasma | 0.2 ng/mL | LC/MS/MS | Validated |
| Ribavirin | Human whole blood | 0.02 ug/mL | LC/MS/MS | Validated |
| Ribavirin | Human Plasma | 0.02 ug/mL | LC/MS/MS | Validated |
| Ribavirin | Human Plasma | 20.0 ng/mL | LC/MS/MS | Validated |
| Ribavirin Total | Human whole blood | 0.2521 ng/mL | LC/MS/MS | Validated |
| Ribavirin Total | Human Plasma | 0.2521 ng/mL | LC/MS/MS | Validated |
| Ribavirin triphosphate | Human Plasma | 100 ng/mL | LC/MS/MS | Under Consideration |
| Ribavirin triphosphate | Human Whole Blood | 100 ng/mL | LC/MS/MS | Under Consideration |
| Ribociclib | Human Plasma | 2.0 ng/mL | LC/MS/MS | Validated |
| Rifabutin | Human Plasma | 2 ng/mL | LC/MS/MS | Validated |
| Rifabutin | Human Plasma | - | LC/MS/MS | Under Development |
| Rifaximin | Human Plasma | 5.0 pg/mL | LC/MS/MS | Validated |
| Rifaximin High Range | Human Plasma | 20.0 pg/mL | LC/MS/MS | Validated |
| Rifaximin Low Range | Human Plasma | 5.0 pg/mL | LC/MS/MS | Validated |
| Rilpivirine | Human Plasma | 0.5 ng/mL | LC/MS/MS | Validated |
| Risperidone | Human Plasma | 0.1 ng/mL | LC/MS/MS | Revalidation Pending |
| Rivaroxaban | Human Plasma | 1.0 ng/mL | LC/MS/MS | Validated |
| Rivastigmine | Human Plasma | 50 pg/mL | LC/MS/MS | Ready for Validation |
| Rivastigmine | Human Plasma | 0.05 ng/mL | LC/MS/MS | Validated |
| Rizatriptan | Human Plasma | 0.2 ng/mL | LC/MS/MS | Validated |
| Roflumilast | Human Plasma | 0.08 ng/mL | LC/MS/MS | Validated |
| Rosuvastatin | Human Plasma | 0.5 ng/mL | LC/MS/MS | Validated |
| Rosuvastatin & N-Desmethyl Rosuvastatin | Human Plasma | 0.1/0.4 ng/mL | LC/MS/MS | Revalidation Pending |
| Rotigotine | Human Plasma | 4.0 pg/mL | LC/MS/MS | Validated |
| Roxithromycin | Human Plasma | 0.06 µg/mL | LC/MS/MS | Validated |
| Rufinamide | Human Plasma | 20.0 ng/mL | LC/MS/MS | Validated |
| S-(+)-Manidipine and R-(-)-Manidipine | Human Plasma | 0.05 (R)/0.05(S) ng/mL | LC/MS/MS | Validated |
| Sacubitril and Valsartan | Human Plasma | 0.01/0.02 µg/mL | LC/MS/MS | Validated |
| Sacubitril and Valsartan | Human Plasma | 2.5/5.0 ng/mL | LC/MS/MS | Validated |
| Sacubitrilat | Human Plasma | 0.025 µg/mL | LC/MS/MS | Validated |
| Sacubitril | Human Plasma | 10.0 ng/mL | LC/MS/MS | Validated |
| Safinamide | Human Plasma | 5.0 ng/mL | LC/MS/MS | Validated |
| Salsalate | Human Plasma | 0.125 µg/mL | LC/MS/MS | Validated |
| Scopolamine | Human Plasma | 1.0 pg/mL | LC/MS/MS | Validated |
| Selexipag and ACT-333679 | Human Plasma | 0.2/0.2 ng/mL | LC/MS/MS | Validated |
| Selexipag and ACT-333679 | Human Plasma | 0.05/0.05 ng/mL | LC/MS/MS | Validated |
| Sertraline and N-Desmethylsertraline | Human Plasma | 0.5/0.5 ng/mL | LC/MS/MS | Revalidation Pending |
| Sildenafil/N-desmethyl Sildenafil | Human Plasma | 1.000 ng/mL | LC/MS/MS | Validated |
| Silodosin & Silodosin Glucuronide | Human Plasma | 0.2/0.3 ng/mL | LC/MS/MS | Validated |
| Simvastatin & Simvastin acid | Human Plasma | 0.1/0.05 ng/mL | LC/MS/MS | Revalidation Pending |
| Sirolimus | Human Blood | 0.15 ng/mL | LC/MS/MS | Validated |
| Sitagliptin | Human Plasma | 2.0 ng/mL | LC/MS/MS | Validated |
| Sofosbuvir and Sofosbuvir metabolite GS331007 | Human Plasma | 5.0/5.0 ng/mL | LC/MS/MS | Validated |
| Sofosbuvir and Velpatasvir | Human Plasma | 20.0/8.0 ng/mL | LC/MS/MS | Validated |
| Sildenafil | Human Plasma | 0.1 ng/mL | LC/MS/MS | Validated |

| | | | | |
|---|--------------|-----------------------|----------|----------------------|
| Sorafenib | Human Plasma | 20.0 ng/mL | LC/MS/MS | Validated |
| Spironolactone | Human Plasma | 0.5 ng/mL | LC/MS/MS | Validated |
| Sulfadoxine and Pyrimethamine | Human Plasma | 1.5/0.004 µg/mL | LC/MS/MS | Validated |
| Sumatriptan | Human Plasma | 1.0 ng/mL | LC/MS/MS | Validated |
| Sunitinib | Human Plasma | 0.6 ng/mL | LC/MS/MS | Validated |
| Sunitinib | Human Plasma | 1.0 ng/mL | LC/MS/MS | Validated |
| Tacrolimus | Human Blood | 0.2 ng/mL | LC/MS/MS | Validated |
| Tadalafil | Human Plasma | 2.0 ng/mL | LC/MS/MS | Validated |
| Tadalafil | Human Plasma | 2.000 ng/mL | LC/MS/MS | Validated |
| Tafamidis | Human Plasma | - | LC/MS/MS | Under Consideration |
| Tamoxifen | Human Plasma | 0.5 ng/mL | LC/MS/MS | Validated |
| Tamsulosin | Human Plasma | 0.2 ng/mL | LC/MS/MS | Validated |
| Telmisartan | Human Plasma | 0.5 ng/mL | LC/MS/MS | Validated |
| Teneligliptin | Human Plasma | 1.0 ng/mL | LC/MS/MS | Validated |
| Tenofovir | Human Plasma | 3.0 ng/mL | LC/MS/MS | Validated |
| Tenofovir Alafenamide | Human Plasma | 1.0 ng/mL | LC/MS/MS | Validated |
| Teriflunomide | Human Plasma | 0.02 µg/mL | LC/MS/MS | Validated |
| Testosterone | Human Serum | 0.05000 ng/mL | LC/MS/MS | Validated |
| Tetrabenazine and Hydroxy Tetrabenazine | Human Plasma | 0.005/0.5 ng/mL | LC/MS/MS | Validated |
| Thalidomide | Human Plasma | 10.0 ng/mL | LC/MS/MS | Validated |
| Theophylline | Human Plasma | 0.05 µg/mL | LC/MS/MS | Validated |
| Thiothixene | Human Plasma | 0.05000 ng/mL | LC/MS/MS | Validated |
| Ticagrelor and AR-C124910XX | Human Plasma | 8.0/2.0 ng/mL | LC/MS/MS | Validated |
| Tiotropium | Human Plasma | 0.2000 pg/mL | LC/MS/MS | Validated |
| Tizanidine | Human Plasma | 0.05 ng/mL | LC/MS/MS | Validated |
| Tizanidine | Human Plasma | 0.1 ng/mL | LC/MS/MS | Validated |
| Tizoxanide | Human Plasma | 0.1 µg/mL | LC/MS/MS | Validated |
| Tofacitinib | Human Plasma | 0.5 ng/mL | LC/MS/MS | Validated |
| Tolterodine and 5-Hydroxy methyl tolterodine | Human Plasma | 0.02/0.02 ng/mL | LC/MS/MS | Validated |
| Tolvaptan | Human Plasma | 0.5 ng/mL | LC/MS/MS | Validated |
| Topiramate | Human Plasma | 2.0 ng/mL | LC/MS/MS | Validated |
| Topiramate | Human Plasma | 50.0 ng/mL | LC/MS/MS | Validated |
| Toremifene | Human Plasma | 5.0 ng/mL | LC/MS/MS | Validated |
| Torseamide | Human Plasma | - | LC/MS/MS | Under Consideration |
| Total Paclitaxel | Human Plasma | 0.1 µg/mL | LC/MS/MS | Validated |
| Tramadol | Human Plasma | 1.0 ng/mL | LC/MS/MS | Validated |
| Tramadol & O-Desmethyltramadol | Human Plasma | 1.0/0.5 ng/mL | LC/MS/MS | Revalidation Pending |
| Trandolapril and Trandolaprilat | Human Plasma | 0.05/0.1 ng/mL | LC/MS/MS | Validated |
| Trazodone | Human Plasma | 20.0 ng/mL | LC/MS/MS | Revalidation Pending |
| Trazodone and M-CPP | Human Plasma | 10.0/0.5 ng/mL | LC/MS/MS | Revalidation Pending |
| Tremaprazine | Dog Plasma | 50 pg/mL | LC/MS/MS | Validated |
| Triamcinolone | Human Plasma | - | LC/MS/MS | Under Consideration |
| Triamcinolone Acetonide | Human Plasma | 0.05 ng/mL | LC/MS/MS | Validated |
| Triamterene | Human Plasma | 3.0 ng/mL | LC/MS/MS | Validated |
| Triamterene and Hydrochlorothiazide | Human Plasma | 2.0/0.5 ng/mL | LC/MS/MS | Validated |
| Triazolam | Human Plasma | 0.1 ng/mL | LC/MS/MS | Validated |
| Trichloroethanol High range | Human Plasma | 0.1 ug/mL | LC/MS/MS | Validated |
| Trichloroethanol low range | Human Plasma | 10 ng/mL | LC/MS/MS | Validated |
| Trientine / N1-Acetyl Trientine | Human Plasma | 10/2.5 ng/mL | LC/MS/MS | Validated |
| Trimetazidine | Human Plasma | 0.5 ng/mL | LC/MS/MS | Validated |
| Trospium | Human Plasma | 0.04 ng/mL | LC/MS/MS | Validated |
| Trospium | Human Plasma | 0.06 ng/mL | LC/MS/MS | Validated |
| Ulipristal acetate | Human Plasma | 0.1 ng/mL | LC/MS/MS | Ready for Validation |
| Ulipristal Acetate | Human Plasma | 2.0 ng/mL | LC/MS/MS | Revalidation Pending |
| Unbound Paclitaxel | Human Plasma | 5.0 ng/mL | LC/MS/MS | Validated |
| Unbound Saroglitazar (NCE-1) | Human Plasma | 5.0 pg/mL | LC/MS/MS | Validated |
| Ursodiol, Glycoursodeoxycholic acid (GUDCA) and Tauroursodeoxycholic acid (TUDCA) | Human Plasma | 0.07/0.07/0.007 µg/mL | LC/MS/MS | Validated |
| Ursodiol, Glycoursodeoxycholic acid (GUDCA) and Tauroursodeoxycholic acid (TUDCA) | Human Plasma | 0.1/0.07/0.002 µg/mL | LC/MS/MS | Validated |
| Valacyclovir & Acyclovir | Human Plasma | 3.0/40.0 ng/mL | LC/MS/MS | Validated |

| | | | | |
|--|--------------|-----------------|----------|-----------|
| Valbenazine and α -Dihydrotrabenazine | Human Plasma | 9.0/0.3 ng/mL | LC/MS/MS | Validated |
| Valproic Acid | Human Plasma | 0.5 μ g/mL | LC/MS/MS | Validated |
| Valsartan | Human Plasma | 0.01 μ g/mL | LC/MS/MS | Validated |
| Vancomycin | Human Plasma | 0.5 μ g/mL | LC/MS/MS | Validated |
| Vardenafil | Human Plasma | 0.125 ng/mL | LC/MS/MS | Validated |
| Varenicline | Human Plasma | 0.05 ng/mL | LC/MS/MS | Validated |
| Venetoclax | Human Plasma | 4.0 ng/mL | LC/MS/MS | Validated |
| Venlafaxine and O-Desmethylvenlafaxine | Human Plasma | 2.0/3.0 ng/mL | LC/MS/MS | Validated |
| Verapamil and Norverapamil | Human Plasma | 1.0/1.0 ng/mL | LC/MS/MS | Validated |
| Vigabatrin | Human Plasma | 0.2 μ g/mL | LC/MS/MS | Validated |
| Vilazodone | Human Plasma | 0.1 ng/mL | LC/MS/MS | Validated |
| Vildagliptin | Human Plasma | 2.0 ng/mL | LC/MS/MS | Validated |
| Voriconazole | Human Plasma | 10.0 ng/mL | LC/MS/MS | Validated |
| Vortioxetine | Human Plasma | 0.05 ng/mL | LC/MS/MS | Validated |
| Warfarin | Human Plasma | 10.0 ng/mL | LC/MS/MS | Validated |
| Zafirlukast | Human Plasma | 2.0 ng/mL | LC/MS/MS | Validated |
| Zidovudine and Lamivudine | Human Plasma | 6.0/6.0 ng/mL | LC/MS/MS | Validated |
| Zileuton | Human Plasma | 0.03 μ g/mL | LC/MS/MS | Validated |
| Ziprasidone | Human Plasma | 0.5 ng/mL | LC/MS/MS | Validated |
| Zolpidem | Human Plasma | 0.5 ng/mL | LC/MS/MS | Validated |

Last updated on 2nd December 2021

[Back](#)

Assay List - Large Molecules

| Analyte | Matrix | Sensitivity | Method |
|--|--------------|---------------|-----------------------|
| Pharmacokinetics (PK) assay | | | |
| Etanercept | Human Serum | 100 ng/mL | ELISA |
| Trastuzumab | Human Serum | 312.5 ng/mL | ELISA |
| Adalimumab | Human Serum | 205.808 ng/mL | ELISA |
| Rituximab | Human Serum | 0.391 ng/mL | ELISA |
| Levothyroxine | Human Serum | 3.5 µg/dL | ELISA |
| Lio thyronine | Human Serum | 0.5 ng/mL | ELISA |
| Erythropoietin | Human Serum | 3.5 mIU/mL | ELISA |
| Bevacizumab | Human Serum | 200.0 ng/mL | ELISA |
| Follicle stimulating hormone (FSH) | Human Serum | 30.0 pg/mL | CMIA |
| GCSF | Human Serum | 250.0 pg/mL | ELISA |
| Peg-GCSF | Human Serum | 250.0 pg/mL | ELISA |
| Teriparatide | Human Plasma | 20.0 pg/mL | ELISA |
| Anti-Heparin-PF4 | Human Serum | NA | ELISA |
| Vitamin B12 | Human Serum | 80.0 pg/mL | CMIA |
| Vitamin B12 | Human Urine | 80.0 pg/mL | CMIA |
| Immunogenicity (ADA & NAB) assay | | | |
| Erythropoietin Anti-drug antibody (ADA) assay | Human Serum | 248.480 ng/mL | ELISA |
| Rituximab Anti-drug antibody (ADA) assay | Human Serum | 59.000 ng/mL | ELISA |
| Bevacizumab Anti-drug antibody (ADA) assay | Human Serum | 51.000 ng/mL | ELISA |
| Adalimumab Anti-drug antibody (ADA) assay | Human Serum | 104.650 ng/mL | ELISA |
| GCSF Anti-drug antibody (ADA) assay | Human Serum | - | ELISA |
| Anti-Heparin-PF4 | Human Plasma | - | ELISA |
| Trastuzumab Anti-drug antibody (ADA) assay | Human Serum | 100.000 ng/mL | ELISA |
| Bevacizumab Neutralizing antibody (NAb) assay | Human Serum | 452.000 ng/mL | ELISA |
| Adalimumab Neutralizing antibody (NAb) assay | Human Serum | 500.000 ng/mL | Cell based |
| Rituximab Neutralizing antibody (NAb) assay | Human Serum | - | Cell based |
| Rituximab Neutralizing antibody (NAb) assay | Human Serum | 750.000 ng/mL | ELISA |
| Pharmacocodynamics (PD) assay | | | |
| Insulin Like Growth Factor-I (IGF-I) | Human Serum | 0.094 ng/mL | ELISA |
| Growth Hormone | Human Serum | 75.0 pg/mL | ELISA |
| Tissue factor pathway inhibitor (TFPI) | Human Plasma | 31.25 ng/mL | ELISA |
| Enoxaparin Sodium Anti Factor IIa | Human Plasma | 0.030 IU/mL | Chromogenic |
| Enoxaparin Sodium Anti Factor Xa (Chromogenic assay) | Human Plasma | 0.050 IU/mL | Chromogenic |
| Enoxaparin sodium Anti Factor Xa (Clotting assay) | Human Plasma | 0.075 IU/mL | Clot based |
| LMWH for APTT | Human Plasma | NA | Clot based |
| LMWH Anti Factor IIa | Human Plasma | 0.030 IU/mL | Chromogenic |
| LMWH Anti Factor Xa | Human Plasma | 0.050 IU/mL | Chromogenic |
| Hep test (LMWH by Anti-Xa) | Human Plasma | 0.075 IU/mL | Clot based |
| Her2 | Human Serum | 78.1 pg/mL | ELISA |
| Glucose | Human Serum | 25 mg/dL | Chromogenic (GOD-POD) |
| Hemolytic potential of drug | Human blood | - | Chromogenic |
| Ghrelin | Human Serum | 46.875 pg/mL | ELISA |
| Leptin | Human Serum | 2.000 ng/mL | ELISA |
| Adiponectin | Human Serum | 0.1 ug/mL | ELISA |
| Immunoglobulin G (IgG) | Human Serum | 3.0 g/L | Turbidimetric |
| Immunoglobulin M (IgM) | Human Serum | 0.4 g/L | Turbidimetric |
| Immunoglobulin A (IgA) | Human Serum | 0.6 g/L | Turbidimetric |
| LMWH HEP Test - EU | Human Plasma | 0.100 IU/mL | Clot based |
| LMWH Anti Factor Xa (Chromogenic assay) - EU | Human Plasma | 0.050 IU/mL | Chromogenic |
| LMWH Anti Factor IIa (Chromogenic assay) - EU | Human Plasma | 0.030 IU/mL | Chromogenic |

| | | | |
|---|--------------|------------------------------------|------------------------------------|
| LMWH for APTT -EU | Human Plasma | NA | Clot based |
| In-Vitro Protein Flocculation | Human Plasma | NA | Chromogenic |
| Platelet Activation | Whole blood | NA | Flow cytometry |
| In-Vitro Hemolytic Index | Whole blood | 0.025 mg/mL | Colorimetric |
| Biomarkers | | | |
| ACH(Acetylcholine) | Human Serum | 31.25 pg/mL | ELISA |
| DA(Dopamine) | Human Serum | 62.5 pg/mL | ELISA |
| EPI(Epinephrine/Adrenaline) | Human Serum | 62.5 pg/mL | ELISA |
| NA/NE(Noradrenaline/Norepinephrine) | Human Serum | 0.63 ng/mL | ELISA |
| ST/5-HT(Serotonin/5-Hydroxytryptamine) | Human Serum | 31.25 ng/mL | ELISA |
| Human MT (Melatonin) | Human Serum | 31.25 pg/mL | ELISA |
| MDA(Malondialdehyde) | Human Serum | 62.5 ng/mL | ELISA |
| 3-NT(3-Nitrotyrosine) | Human Serum | 3.13 ng/mL | ELISA |
| 8-epi-PGF2 α (8-Epi-Prostaglandin F2 Alpha), Isoprostane | Human Serum | 31.25 pg/mL | ELISA |
| Human SOD1 (Superoxide Dismutase 1, Soluble) | Human Serum | 125 pg/mL | ELISA |
| Human MCP-1(Monocyte Chemotactic Protein 1) | Human Serum | 31.25 pg/mL | ELISA |
| Human OxLDL(Oxidized Low Density Lipoprotein) | Human Serum | 62.5 pg/mL | ELISA |
| Catalase | Human Serum | 31.25 pg/mL | ELISA |
| Adiponectin | Human Serum | 4.90 - 9.10 μ g/mL | ELISA |
| Klotho | Human Serum | 0.31 - 20.0 ng/mL | ELISA |
| Vitamin-C | Human Serum | 1.56 - 100 μ g/mL | ELISA |
| 1,25-dihydroxy vitamin D3 | Human Serum | 7.81 - 500.0 pg/mL | ELISA |
| Oxytocin | Human Serum | 15.63 - 1000.0 pg/mL | ELISA |
| CD 19 count % | Whole blood | 0.0 - 95.5 % | Flow cytometry |
| Absolute CD 19 count | Whole blood | 0.0 – 63851 cell/ μ L | Flow cytometry |
| IL-2 | Serum | 0.0 - 2500 pg/ml | Flow cytometry |
| IL-4 | Serum | 0.0 - 2500 pg/ml | Flow cytometry |
| IL-6 | Serum | 0.0 - 2500 pg/ml | Flow cytometry |
| IL-8 | Serum | 0.0 - 2500 pg/ml | Flow cytometry |
| IL-10 | Serum | 0.0 - 2500 pg/ml | Flow cytometry |
| TNF-alfa | Serum | 0.0 - 2500 pg/ml | Flow cytometry |
| INF-gmma | Serum | 0.0 - 2500 pg/ml | Flow cytometry |
| IL-1beta | Serum | 0.0 - 2500 pg/ml | Flow cytometry |
| CD34 count | Whole blood | - | Flow cytometry |
| Cell Based In-vitro, Biomarker & NAB assays | | | |
| Adalimumab NAB assay | Human Serum | 500.0 ng/mL | Cell based/ Fluorescence |
| Cytokine release assay | PBMC | NA | Cell based/ Absorbance |
| Rituximab NAB assay | In-vitro | - | Cell based/ Luminescence |
| NK Cell Activity assay | Whole blood | NA | Cell based/ Flow cytometry |
| Vaccine | | | |
| Measles Virus IgG | Serum | 50 - 5000 mIU/mL | ELISA |
| Mumps Virus IgG | Serum | 1 to 150 U/mL | ELISA |
| Rubella Virus IgG | Serum | 10 - 500 IU/mL | ELISA |
| Diphtheria toxoid IgG | Serum | 0.01 to 1.0 IU/mL | ELISA |
| Bordetella Pertusis IgG | Serum | 1 to 150 U/mL | ELISA |
| Tetanus toxoid IgG | Serum | 0.1 to 5.0 IU/mL | ELISA |
| Varicells Zoster Virus IgG | Serum | 10 - 810 mIU/mL | ELISA |
| Haemophilus Influenzae Type B IgG | Serum | H1N1, H3N2, B/Yamagata, B/Victoria | Haemagglutination inhibition assay |
| Anti Hepatitis B Surface Antigen (HBs) IgG | Serum | 0 - 1000 mIU/mL | CMIA |
| Anti-S Typhi Vi IgG | Serum | 7.4 - 600 U/mL | ELISA |

Last updated on 2nd December 2021

Back

IVRT/IVPT Methods

| Analyte | Strength | Method | Receptor Media | Membrane | Curve range |
|---|----------------|--------|--|--------------------------------|-----------------|
| Acyclovir | 5% cream | IVRT | 1.0 % HCl:IPA (80:20) | Nylon, 25 mm, 0.45µm | 3-300 µg/mL |
| Acyclovir | 5% cream | IVPT | Phosphate buffer saline (PBS) with 0.1% sodium azide | Strat-M | 20-2000 ng/mL |
| Acyclovir | 5% cream | IVPT | Water:PG (80:20) | Nylon, 25 mm, 0.45µm | 0.1-15 µg/mL |
| Betamethasone dipropionate | 0.05% cream | IVRT | 60% Alcohol-Water | Supor 25 mm, 0.45µm | 2.5-200 µg/mL |
| Clindamycine Phosphate and Benzoyl Peroxide | (1.2%/5%) Gel | IVRT | 60% IPA with 0.02% H3PO4 | Cellulose Nitrate 25mm, 0.45µm | 3-300 µg/mL |
| Clobetasol Propionate | 0.5% cream | IVRT | 50% polyglycol (PG) | Supor 25 mm, 0.45µm | 0.1-5 µg/mL |
| Clobetasol Propionate | 0.5% cream | IVRT | 80% polyglycol (PG) | Supor 25 mm, 0.45µm | 0.1-5 µg/mL |
| Clobetasol Propionate | 0.05% Ointment | IVRT | 50% THF | Nylon 25 mm, 0.45µm | 0.25-12.5 µg/mL |
| Crisaborole | 2% Ointment | IVRT | 0.5%Acetic acid: IPA:THF(70:15:15) | Nylon, 25 mm, 0.45µm | 2-200 µg/mL |
| Dapsone | 5% Gel | IVRT | 30% Ethanol | Nylon, 25 mm, 0.45µm | 3-300 µg/mL |
| Dapsone | 5% Gel | IVPT | Phosphate buffer saline (PBS) with 0.1% sodium azide | Strat-M | 100-20000 ng/mL |
| Hydrocortisone | 1% cream | IVRT | 30% Ethanol | H T Tuffryn 25 mm, 0.45µm | 9-80 µg/mL |
| Hydrocortisone | 1% cream | IVPT | Phosphate buffer saline (PBS) with 0.1% sodium azide | Strat-M | 260-3000 ng/mL |
| Dapsone | 5% Gel | IVPT | Phosphate buffer saline (PBS) with 0.1% sodium azide | Human Skin | 0.1-20 µg/mL |
| Doxepin | 5% Cream | IVRT | Ammonium Formate pH 4.5 | Nylon, 25 mm, 0.45µm | 10-100 ug/mL |

Last updated on 2nd December 2021

[Back](#)